Thimerosal Vaccine Removal: HHS Finalizes Decision

By HEOR Staff Writer

July 24, 2025

The U.S. Department of Health and Human Services (HHS) has finalized its decision to remove thimerosal from influenza vaccines. This follows a 2025 CDC committee vote to limit thimerosal to single-dose, mercury-free formulations for children, pregnant women, and adults. HHS Secretary Robert F. Kennedy Jr. called the move necessary, despite scientific consensus on thimerosal’s safety.

Key Insights

  1. Controversial Policy Shift: The decision breaks from decades of research supporting thimerosal’s safety. Over 40 studies found no harm from low-dose exposure. Critics say it may erode vaccine trust.
  2. Logistical Readiness: Manufacturers confirm they can replace multi-dose vials with thimerosal-free options.
  3. Global Alignment: The U.S. now aligns with Europe’s phase-out, though only 4% of U.S. flu vaccines contained thimerosal.

Background Context
Thimerosal has been used since the 1930s to prevent vaccine contamination. In 1999, authorities recommended reducing mercury exposure in children. By 2023, all pediatric vaccines were thimerosal-free. The CDC and FDA maintain that its safety risks are negligible.

Implications

  1. Health Economics: Single-dose formulations may raise costs but won’t disrupt supply chains.
  2. Public Trust: The policy risks validating debunked fears about autism or toxicity.
  3. Legal Challenges: Groups like the IDSA may sue, calling the changes unscientific.

 

Reference url

Recent Posts

NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation
Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...